2STADLER M, CERMING U, KLICHE K O, et al. A prospective, randomised, phase Ⅱ study of horse antitbymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes[J].Leukemia, 2004, 18 (3) : 460-465.
3STEENSMA D P, DISPENZIERI A, MOORE S B, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselccted anemic patients with myelodysplastie syndrome[ J ]. Blood, 2003, 101 ( 6 ):2156-2158.
4SAUNTHARARAJAH Y, NAKAMURA R, NAM J M, et al. HLA-DR15( DR2 ) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome[J]. Blood, 2002, 100 (2): 1570-1574.
5KOCHENDERFER J N, KOBAYASHI S, WIEDER E D, et al. Loss of Tlymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosupprcssion[J]. Blood, 2002, 100 (10): 3639-3645.
6OGATA M, OHTSUKA E, IMAMURA T, et al. Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review[J]. Int J Hematol, 2004, 80 (1): 35-42.
7SHIMAMOTO T, TOHYAMA K, OKAMOTO T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan[J]. Leuk Res, 2003,27 (9) : 783-788.
8RAZA A, MEYER P, DUTr D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes[J]. Blood, 2001,98 (4): 958-965.
9STRUPP C, GERMING U, HILDEBRANDT B, et al. Thalidomide for the treatment ofmyelodysplastic syndromes[J]. Leuk Res, 2002, 27(Suppl 1) : S107-S108.
10MORENO-ASPITIA A, GEYER S, LI C Y, et al.N998B: multicenter phase Ⅱ trial of thalidomide in adult patients with myelodysplastic syndromes[J]. Blood.2002,100(1):96.
